AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25374047 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided message acknowledging a serious objection (fear of testing positive for HIV)
Number of subjects: 1919
Study 25374047 — intervention group
Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 1919
Study 22173140 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass distribution of a single dose of oral azithromycin for trachoma
Number of subjects: 1036
Study 22173140 — intervention group
Group type: COMPARATOR
Intervention: Nontreated communities (control)
Number of subjects: 1036
Study 21526662 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) with propofol 4 microg/ml and remifentanil 4 ng/ml
Number of subjects: 60
Study 21526662 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) with conventional-dose-weight infusion method
Number of subjects: 60
Study 21526662 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI)
Number of subjects: 60
Study 21526662 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI)
Number of subjects: 60
Study 17671052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside case presentation
Number of subjects: 27
Study 17671052 — intervention group
Group type: COMPARATOR
Intervention: Conference-room case presentation
Number of subjects: 27
Study 15836571 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mg subcutaneous sumatriptan
Number of subjects: 30
Study 15836571 — intervention group
Group type: COMPARATOR
Intervention: 6-mg subcutaneous sumatriptan
Number of subjects: 30
Study 11950434 — intervention group
Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM)
Number of subjects: 57
Study 11950434 — intervention group
Group type: COMPARATOR
Intervention: Modern medicine (conventional dietary, exercise, and multivitamin approaches)
Number of subjects: 57
Study 11950434 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no added intervention)
Number of subjects: 57
Study 11950434 — intervention group
Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM) for high-risk subjects
Number of subjects: 57
Study 11950434 — intervention group
Group type: COMPARATOR
Intervention: Usual care for high-risk subjects
Number of subjects: 57
Study 11950434 — intervention group
Group type: COMPARATOR
Intervention: Modern medicine for high-risk subjects
Number of subjects: 57
Study 11950434 — intervention group
Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Medicine (MVM) overall
Number of subjects: 57
Study 9452325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 335
Study 9452325 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 335
Study 9452325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 335
Study 8590577 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole sulphoxide (ABZS) administered orally
Number of subjects: 0
Study 8590577 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (ABZ) administered orally
Number of subjects: 0
Study 2273117 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate closure (group A, n = 10 patients)
Number of subjects: 25
Study 2273117 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged procedures such as Mohs micrographic surgery (group B, n = 15 patients)
Number of subjects: 25
Study 81655 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosiplex (drug-treated patients)
Number of subjects: 13
Study 81655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study 31928489 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit device and buddy system
Number of subjects: 13
Study 31928489 — intervention group
Group type: COMPARATOR
Intervention: Automated text messages
Number of subjects: 13
Study 31050628 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim with MIC > 8 µg/ml
Number of subjects: 790
Study 31050628 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 790
Study 27221810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical occlusion chemically assisted endovenous ablation (MOCA)
Number of subjects: 170
Study 27221810 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency endovenous ablation (RFA)
Number of subjects: 170
Study 25413621 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (0.7 mA for 10 minutes applied to bilateral primary motor cortices)
Number of subjects: 13
Study 25413621 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study 23458162 — intervention group
Group type: EXPERIMENTAL
Intervention: Veriset™ haemostatic patch
Number of subjects: 50
Study 23458162 — intervention group
Group type: COMPARATOR
Intervention: Fibrin sealant patch (TachoSil(®))
Number of subjects: 50
Study 21191313 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored individual doses of radioiodine (¹³¹I) and low-dose antithyroid drug (ATD)
Number of subjects: 118
Study 21191313 — intervention group
Group type: COMPARATOR
Intervention: Control group with fixed dose of radioiodine set as 2.96 MBq/g of thyroid
Number of subjects: 118
Study 21191313 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ATD used in study group
Number of subjects: 118
Study 19904665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP)
Number of subjects: 168
Study 19904665 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 168
Study 16571905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondominant hand movements during intentional switches between in-phase and antiphase coordination patterns.
Number of subjects: 0
Study 16571905 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-handed participants performing voluntary switches.
Number of subjects: 0
Study 16571905 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-handed participants performing voluntary switches.
Number of subjects: 0
Study 16571905 — intervention group
Group type: EXPERIMENTAL
Intervention: Switches from in-phase to antiphase coordination.
Number of subjects: 0
Study 12682825 — intervention group
Group type: EXPERIMENTAL
Intervention: benfluorex (150-450 mg/day)
Number of subjects: 722
Study 12682825 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 722
Study 12682825 — intervention group
Group type: EXPERIMENTAL
Intervention: benfluorex
Number of subjects: 722
Study 12682825 — intervention group
Group type: COMPARATOR
Intervention: metformin
Number of subjects: 722
Study 10548199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 7.2%-hydroxyethyl starch 6% solution (HS-HES group)
Number of subjects: 26
Study 10548199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 7.2% solution (HS group)
Number of subjects: 26
Study 10548199 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethyl starch 6% solution (HES group)
Number of subjects: 26
Study 8913317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 0
Study 8913317 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 0
Study 8913317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (before and after treatment)
Number of subjects: 0
Study 8913317 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects' lymphocytes
Number of subjects: 0
Study 1760997 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid diet
Number of subjects: 59
Study 1760997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet
Number of subjects: 59
Study 1760997 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet
Number of subjects: 59
Study 7199345 — intervention group
Group type: EXPERIMENTAL
Intervention: Remid preparation of allopurinol, 300 mg p.o. dose
Number of subjects: 10
Study 7199345 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation of allopurinol, 300 mg p.o. dose
Number of subjects: 10
Study 31873950 — intervention group
Group type: EXPERIMENTAL
Intervention: SND without level 2b dissection (group 1)
Number of subjects: 30
Study 31873950 — intervention group
Group type: COMPARATOR
Intervention: SND with level 2b dissection (group 2)
Number of subjects: 30
Study 31712574 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory tDCS during initial training
Number of subjects: 100
Study 31712574 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 100
Study 31712574 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitatory tDCS during incubation period
Number of subjects: 100
Study 28832406 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 165
Study 28832406 — intervention group
Group type: COMPARATOR
Intervention: Baseline total 25‐(OH)D
Number of subjects: 165
Study 28832406 — intervention group
Group type: COMPARATOR
Intervention: Baseline bioavailable 25‐(OH)D
Number of subjects: 165
Study 26498331 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders sent to parents before EPI sessions
Number of subjects: 523
Study 26498331 — intervention group
Group type: COMPARATOR
Intervention: Ordinary methods of informing parents
Number of subjects: 523
Study 23465966 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 69
Study 23465966 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia and bipolar patients
Number of subjects: 69
Study 21621629 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP) administered 3 times during week 1, then twice weekly until week 12, followed by 2 treatments monthly until week 24.
Number of subjects: 29
Study 21621629 — intervention group
Group type: COMPARATOR
Intervention: Standard of care non-ECP (control) arm
Number of subjects: 29
Study 18945998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral DXA measurement of aortic VC
Number of subjects: 40
Study 18945998 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measurement of aortic VC
Number of subjects: 40
Study 18945998 — intervention group
Group type: COMPARATOR
Intervention: Lateral DXA VC > or = 6 on a 24-point scale
Number of subjects: 40
Study 18945998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral DXA-reported BMD
Number of subjects: 40
Study 18945998 — intervention group
Group type: COMPARATOR
Intervention: AP DXA-reported BMD
Number of subjects: 40
Study 16568198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 105
Study 16568198 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron-Propofol (5 mg tropisetron and 0.5 mg/kg propofol)
Number of subjects: 105
Study 16568198 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 105
Study 12937042 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (fish oil capsules rich in DHA)
Number of subjects: 100
Study 12937042 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (placebo capsules)
Number of subjects: 100
Study 12937042 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA status of infants at birth
Number of subjects: 100
Study 11079527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (80%, 1-RM, 8 reps)
Number of subjects: 25
Study 11079527 — intervention group
Group type: EXPERIMENTAL
Intervention: High-repetition resistance training (40%, 1-RM, 16 reps)
Number of subjects: 25
Study 11079527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 9762660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin synthesis (IgA, IgG, IgM) and complement activation in MS patients
Number of subjects: 48
Study 9762660 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal immunoglobulin synthesis (IgG, IgA, IgM)
Number of subjects: 48
Study 9762660 — intervention group
Group type: EXPERIMENTAL
Intervention: Full activation of the complement cascade
Number of subjects: 48
Study 7918843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (Livial)
Number of subjects: 30
Study 7918843 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate combined with cyproterone acetate (Climen)
Number of subjects: 30
Study 3414321 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 13
Study 3414321 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanthelene
Number of subjects: 13
Study 29686009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (target diastolic blood pressure, 85 mm Hg)
Number of subjects: 981
Study 29686009 — intervention group
Group type: COMPARATOR
Intervention: Less-tight control (target diastolic blood pressure, 100 mm Hg)
Number of subjects: 981
Study 28490514 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU cholecalciferol bolus followed by 4000 IU cholecalciferol/d)
Number of subjects: 65
Study 28490514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 28490514 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 65
Study 26109261 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-questionnaire completed on a dedicated website
Number of subjects: 1141
Study 26109261 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 1141
Study 24685788 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock dentin desensitizer (Bisco Inc.)
Number of subjects: 30
Study 24685788 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse desensitizer (GC Asia)
Number of subjects: 30
Study 24685788 — intervention group
Group type: COMPARATOR
Intervention: Systemp desensitizer (Ivoclar Vivadent)
Number of subjects: 30
Study 24685788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no desensitizer application)
Number of subjects: 30
Study 21122499 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-MMX® 9 mg tablets
Number of subjects: 36
Study 18261024 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 51
Study 18261024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 17052562 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐minute nap opportunity at 3 AM
Number of subjects: 49
Study 12386359 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer closure of the vaginal cuff
Number of subjects: 427
Study 12386359 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer closure of the vaginal cuff
Number of subjects: 427
Study 12386359 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vaginal cuff
Number of subjects: 427
Study 10464783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/die)
Number of subjects: 14
Study 10464783 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion in 4 patients
Number of subjects: 14
Study 10464783 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-apheresis
Number of subjects: 14
Study 10464783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 14
Study 7598013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing dietary saturated fat
Number of subjects: 0
Study 7598013 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet
Number of subjects: 0
Study 7598013 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated fat diet
Number of subjects: 0
Study 7598013 — intervention group
Group type: COMPARATOR
Intervention: Specific saturated fatty acids
Number of subjects: 0
Study 2142294 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 240 mg p.o. 3 hours before exercise challenge
Number of subjects: 6
Study 2142294 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063 5 mg by inhalation 30 minutes before exercise challenge
Number of subjects: 6
Study 2142294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 349439 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinestrol 2 mg single dose
Number of subjects: 134
Study 349439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tace 72 mg every 12 hours for 2 days
Number of subjects: 134
Study 349439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 7115012 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine hydrochloride, 150 mg daily
Number of subjects: 28
Study 7115012 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline hydrochloride, 150 mg daily
Number of subjects: 28
Study 7115012 — intervention group
Group type: COMPARATOR
Intervention: Control group (pretreatment HPA variables)
Number of subjects: 28
Study 30727721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.75 mg/m2 IV) and gemcitabine (starting dose 700 mg/m2 with increments of 100 mg/m2) administered on days 1, 8, and 15 every 28 days.
Number of subjects: 24
Study 30504736 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (80–325 mg)
Number of subjects: 5000
Study 26900146 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 mcg subcutaneously daily)
Number of subjects: 94
Study 26900146 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 94
Study 26900146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94
Study 25485672 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention group
Number of subjects: 98
Study 25485672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 22267762 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38
Study 22267762 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 38
Study 19827506 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat pack
Number of subjects: 18
Study 19827506 — intervention group
Group type: COMPARATOR
Intervention: No heat pack
Number of subjects: 18
Study 19827506 — intervention group
Group type: COMPARATOR
Intervention: Dry nonheated heat pack
Number of subjects: 18
Study 17970961 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA parameters with T-end cursor moved backward and forward (+/- 8 ms)
Number of subjects: 30
Study 17970961 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA parameters at long-term evaluation
Number of subjects: 30
Study 16306738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal approach for obturator nerve block
Number of subjects: 50
Study 16306738 — intervention group
Group type: COMPARATOR
Intervention: Pubic tubercle approach for obturator nerve block
Number of subjects: 50
Study 11873026 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 459
Study 11873026 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine analgesia
Number of subjects: 459
Study 10448773 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Educational Program (IEP)
Number of subjects: 77
Study 10448773 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 77
Study 7598580 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 28 degrees C
Number of subjects: 30
Study 7598580 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 32 degrees C
Number of subjects: 30
Study 7598580 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB perfusion temperature at 37 degrees C
Number of subjects: 30
Study 2193511 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion (n = 30)
Number of subjects: 60
Study 627129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous labetalol (1.5 mg/kg)
Number of subjects: 6
Study 31651183 — intervention group
Group type: EXPERIMENTAL
Intervention: CJDHWSWT plus eye drops systane ultra for 90 days
Number of subjects: 30
Study 31651183 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group (defined eye drops only)
Number of subjects: 30
Study 31651183 — intervention group
Group type: EXPERIMENTAL
Intervention: CJDHWSWT plus eye drops systane ultra
Number of subjects: 30
Study 31349862 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg daily aspirin
Number of subjects: 27
Study 31349862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 29895406 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT-ACT
Number of subjects: 14
Study 29895406 — intervention group
Group type: COMPARATOR
Intervention: SIT
Number of subjects: 14
Study 29895406 — intervention group
Group type: COMPARATOR
Intervention: CONT-SIT
Number of subjects: 14
Study 27023008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime glargine
Number of subjects: 15
Study 27023008 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice‐daily detemir
Number of subjects: 15
Study 27023008 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 15
Study 24563178 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 20
Study 24563178 — intervention group
Group type: EXPERIMENTAL
Intervention: aura-i
Number of subjects: 20
Study 24563178 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 20
Study 24563178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrack
Number of subjects: 20
Study 22608262 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A (TTF)
Number of subjects: 237
Study 22608262 — intervention group
Group type: COMPARATOR
Intervention: Active chemotherapy
Number of subjects: 237
Study 19174791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet for cow's milk, egg, and soy proteins for 8 weeks
Number of subjects: 33
Study 17933738 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance goals
Number of subjects: 0
Study 17933738 — intervention group
Group type: COMPARATOR
Intervention: Mastery goals or no goal
Number of subjects: 0
Study 15893011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (T) 1.0 mg/m2 d 1-5 and Cisplatin (DDP) 75 mg/m2 d 5 (arm A)
Number of subjects: 86
Study 15893011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (T) 1.5 mg/m2 d 1-3 and Cisplatin (DDP) 75 mg/m2 d 3 (arm B)
Number of subjects: 86
Study 11826245 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (Nutropin, 1 mg/m2/day)
Number of subjects: 54